Lumos lifts operating cash flow on FebriDx momentum as 1H FY26 loss widens Proactive uses images sourced from Shutterstock Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported revenue of US$6.12 million for the six months to December 31, 2025 (1H FY26), down slightly from US$6.31 million a year earlier, as the company progressed multiple FebriDx commercial and regulatory milestones in the US. Product sales rose, led by FebriDx, with sale of goods increasing to US$1.68 million from US$0.84 mil ...